Log in

NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Forecast & News

$8.35
-0.24 (-2.79 %)
(As of 02/16/2020 03:07 PM ET)
Add
Today's Range
$8.28
Now: $8.35
$8.67
50-Day Range
$6.59
MA: $7.42
$8.59
52-Week Range
$4.47
Now: $8.35
$16.67
Volume158,633 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PTGX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees64
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.


Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.61) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.10. The company earned $4.14 million during the quarter, compared to analyst estimates of $5.75 million. View Protagonist Therapeutics' Earnings History.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Protagonist Therapeutics.

What price target have analysts set for PTGX?

5 Wall Street analysts have issued 1-year target prices for Protagonist Therapeutics' shares. Their forecasts range from $17.00 to $29.00. On average, they expect Protagonist Therapeutics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 157.5% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.

What is the consensus analysts' recommendation for Protagonist Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.

Has Protagonist Therapeutics been receiving favorable news coverage?

News articles about PTGX stock have trended neutral recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Protagonist Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Protagonist Therapeutics.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 1,240,000 shares, a decrease of 20.5% from the January 15th total of 1,560,000 shares. Based on an average daily trading volume, of 660,800 shares, the days-to-cover ratio is currently 1.9 days. Currently, 6.5% of the shares of the company are short sold. View Protagonist Therapeutics' Current Options Chain.

What other stocks do shareholders of Protagonist Therapeutics own?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)
  • Dr. Richard S. Shames, Chief Medical Officer (Age 59)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
  • Dr. Mark Smythe, VP of Technology (Age 54)
  • Dr. Samuel R. Saks, Chief Devel. Officer (Age 64)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Renaissance Technologies LLC (2.27%), State Street Corp (1.24%), Jacobs Levy Equity Management Inc. (0.34%), Bank of New York Mellon Corp (0.31%) and Ikarian Capital LLC (0.29%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Richard S Shames, Suneel Gupta and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

Which institutional investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management LLP, Russell Investments Group Ltd., Bank of America Corp DE and Eqis Capital Management Inc.. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Ikarian Capital LLC, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Prudential Financial Inc., Spark Investment Management LLC, State Street Corp and Strs Ohio. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen and Suneel Gupta. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $8.35.


MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel